Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–31 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Interventions
INZ-701, Control Arm (Conventional Therapy)
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
1 Year to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced May 21, 2026, 7:24 PM EDT
Conditions
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Rochester, Minnesota • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced May 21, 2026, 7:24 PM EDT
Conditions
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
Up to 1 Year
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 7:24 PM EDT
Conditions
Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
Interventions
Burosumab
Biological
Lead sponsor
Redwood Dermatology Sciences
Other
Eligibility
Up to 18 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced May 21, 2026, 7:24 PM EDT
Conditions
Epidermal Nevus Syndrome
Interventions
Crysvita (burosumab-twza) Treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Months and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced May 21, 2026, 7:24 PM EDT
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
5 Years to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced May 21, 2026, 7:24 PM EDT
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Interventions
No Intervention for this observational study
Other
Lead sponsor
Inozyme Pharma
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 21, 2026, 7:24 PM EDT